{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:15:24Z","timestamp":1784175324845,"version":"3.55.0"},"reference-count":90,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapies have revolutionised the field of haematological malignancies by achieving impressive remission rates in patients with highly refractory haematological malignancies, improving overall survival. To date, six commercial anti-CD19 and anti-BCMA CAR T-cell products have been approved by the Food and Drug Administration (FDA) for the treatment of relapsed\/refractory B-cell haematological malignancies and multiple myeloma. The indications for CAR T-cell therapies are gradually expanding, with these therapies being investigated in a variety of diseases, including non-malignant ones. Despite the great success, there are several challenges surrounding CAR T-cell therapies, such as non-durable responses and high-grade toxicities. In addition, a new safety concern was added by the FDA on 28 November 2023 following reports of T-cell malignancies in patients previously treated with either anti-CD19 or anti-BCMA autologous CAR T-cell therapies both in clinical trials and in the real-world setting. Since then, several reports have been published presenting the incidence and analysing the risks of other secondary malignancies after CAR T-cell therapies. In this opinion article, the current landscape of secondary malignancies after CAR T-cell therapies is presented, along with a proposed strategy for future research aiming at potentially diminishing or abrogating the risk of developing secondary malignancies after CAR T-cell therapies.<\/jats:p>","DOI":"10.3390\/ijms25179518","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T12:22:33Z","timestamp":1725366153000},"page":"9518","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-3885","authenticated-orcid":false,"given":"Stella","family":"Bouziana","sequence":"first","affiliation":[{"name":"Department of Hematology, King\u2019s College Hospital, London SE59RS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1750-657X","authenticated-orcid":false,"given":"Dimitrios","family":"Bouzianas","sequence":"additional","affiliation":[{"name":"BReMeL, Biopharmaceutical and Regenerative Medicine Laboratories, 55534 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Guerra, E., Di Pietro, R., Basile, M., Trerotola, M., and Alberti, S. (2022). Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010405"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e20230903","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Khericha","year":"2024","journal-title":"J. Exp. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q., and He, B. (2023). From bench to bedside: The history and progress of CAR T cell therapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1188049"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","article-title":"Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes","volume":"3","author":"Korell","year":"2022","journal-title":"Med"},{"key":"ref_6","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti\u2013B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_9","unstructured":"(2024, April 26). Approved Cellular and Gene Therapy Products. US Food & Drug Administration, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products."},{"key":"ref_10","unstructured":"(2024, March 03). U.S. FDA Approves Bristol Myers Squibb\u2019s Breyanzi as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Available online: https:\/\/news.bms.com\/news\/details\/2024\/U.S.-FDA-Approves-Bristol-Myers-Squibbs-Breyanzi--as-the-First-and-Only-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukemia-CLL-or-Small-Lymphocytic-Lymphoma-SLL\/default.aspx."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukemia remissions with the persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"103096","DOI":"10.1016\/j.critrevonc.2020.103096","article-title":"Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy","volume":"157","author":"Bouziana","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol. Cancer."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","article-title":"Next-Generation CAR T-cell Therapies","volume":"12","author":"Young","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): A phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2023-179868","article-title":"Five year outcomes of patients with large B-Cell lymphoma treated with standard-of-care Axicabtagene Ciloleucel: Results from the US lymphoma CAR-T cell consortium","volume":"142","author":"Spiegel","year":"2023","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1158\/0008-5472.CAN-22-2220","article-title":"Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors","volume":"83","author":"Zhong","year":"2023","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease\u2014A Case Series with Follow-up","volume":"390","author":"Taubmann","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: The evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"ref_22","unstructured":"(2023, November 28). FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. US Food & Drug Administration, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS)","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"key":"ref_26","unstructured":"(2024, April 18). FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. US Food & Drug Administration, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1182\/blood-2023-178806","article-title":"CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma","volume":"142","author":"Harrison","year":"2023","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/mt.2013.67","article-title":"Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1","volume":"21","author":"Heinrich","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood-2023-182817","article-title":"C-CAR039, a Novel Anti-CD20\/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r\/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood.2022015728","article-title":"Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs","volume":"140","author":"Steffin","year":"2022","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.2020010497","article-title":"The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma","volume":"138","author":"Chihara","year":"2021","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Lymphoma Program Investigators at the University of Pennsylvania. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.21971","article-title":"The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma","volume":"107","author":"Tward","year":"2006","journal-title":"Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1182\/bloodadvances.2022008093","article-title":"Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy","volume":"6","author":"Hsieh","year":"2022","journal-title":"Blood Adv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large b-cell lymphoma","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1097\/HS9.0000000000000957","article-title":"Clinical implications and dynamics of clonal hematopoiesis in anti- CD19 CAR T-cell treated patients","volume":"7","author":"Panagiota","year":"2023","journal-title":"Hemasphere"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/bloodadvances.2021005747","article-title":"Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment","volume":"6","author":"Teipel","year":"2022","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2023-182522","article-title":"CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias","volume":"142","author":"Hamilton","year":"2023","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-022-00707-4","article-title":"Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma","volume":"12","author":"Alkhateeb","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","article-title":"Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy","volume":"5","author":"Miller","year":"2021","journal-title":"Blood Adv."},{"key":"ref_46","first-page":"2620","article-title":"CAR T cells reside in the bone marrow and inhibit hematopoiesis","volume":"8","author":"Ahmadreza","year":"2024","journal-title":"HemaSphere"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Zhao, A., Zhao, M., Qian, W., Liang, A., Li, P., and Liu, H. (2023). Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory\/relapsed B-cell lymphoma: Case series and review of literature. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1063986"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3324\/haematol.12120","article-title":"Secondary malignancies after treatment for indolent non-Hodgkin\u2019s lymphoma: A 16-year follow-up study","volume":"93","author":"Sacchi","year":"2008","journal-title":"Haematologica"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/bloodadvances.2023012336","article-title":"Answering the \u201cDoctor, can CAR-T therapy cause cancer?\u201d question in clinic","volume":"8","author":"Banerjee","year":"2024","journal-title":"Blood Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e6718317","DOI":"10.1097\/01.HS9.0000967964.67183.17","article-title":"Cytopenias, age and CAR-HEMATOTOX score predict the development of post CAR T-cell therapy-related myeloid neoplasms","volume":"7","author":"Gurney","year":"2023","journal-title":"Hemasphere"},{"key":"ref_51","first-page":"398","article-title":"Predicting therapy-related myeloid neoplasms after CAR-T: Validation of the clonal hematopoiesis risk score (CHRS)","volume":"8","author":"Galli","year":"2024","journal-title":"HemaSphere"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global Manufacturing of CAR T Cell Therapy","volume":"4","author":"Levine","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich Syndrome\u2014Long-term reconstitution and clinical benefits, but increased risk for leukemogenesis","volume":"6","author":"Braun","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/hum.2013.2527","article-title":"Adenovirus: The first effective in vivo gene delivery vector","volume":"25","author":"Crystal","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/B978-0-12-386509-0.00003-X","article-title":"Retrovirus and lentivirus vector design and methods of cell conditioning","volume":"507","author":"Cooray","year":"2012","journal-title":"Methods Enzymol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/toxsci\/kfw220","article-title":"Viral Vectors: The Road to Reducing Genotoxicity","volume":"155","author":"David","year":"2017","journal-title":"T Toxicol. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Labb\u00e9, R.P., Vessillier, S., and Rafiq, Q.A. (2021). Lentiviral vectors for T cell engineering: Clinical applications, bioprocessing and future perspectives. Viruses, 13.","DOI":"10.3390\/v13081528"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1172\/JCI61852","article-title":"Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts","volume":"122","author":"Moiani","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/mt.2014.3","article-title":"Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo","volume":"22","author":"Cesana","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","article-title":"Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy","volume":"3","author":"Shah","year":"2019","journal-title":"Blood Adv."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Payen","year":"2010","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/14712598.2022.2124857","article-title":"Treatment of cerebral adrenoleukodystrophy: Allogeneic transplantation and lentiviral gene therapy","volume":"22","author":"Gupta","year":"2022","journal-title":"Exp. Opin. Biol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2017-05-783233","article-title":"Increased risk of leukemia among sickle cell disease patients in California","volume":"130","author":"Brunson","year":"2017","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/bloodadvances.2019001330","article-title":"Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease","volume":"4","author":"Hsieh","year":"2020","journal-title":"Blood Adv."},{"key":"ref_72","unstructured":"(2021, March 29). Global Newswire Uniqure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program. Available online: https:\/\/www.globenewswire.com\/news-release\/2021\/03\/29\/2200653\/0\/en\/uniQure-Announces-Findings-from-Reported-Case-of-Hepatocellular-Carcinoma-HCC-in-Hemophilia-B-Gene-Therapy-Program.html."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_77","unstructured":"(2023, December 08). FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. US Food & Drug Administration, Available online: www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cr.2016.142","article-title":"CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1016\/j.cell.2023.08.041","article-title":"Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells","volume":"186","author":"Tsuchida","year":"2023","journal-title":"Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41467-022-28244-5","article-title":"CRISPR-Cas9 induces large structural variants at on-target and off-target sites in vivo that segregate across generations","volume":"13","author":"Emmanouilidou","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"503767","DOI":"10.1016\/j.mrgentox.2024.503767","article-title":"Non-clinical safety assessment of novel drug modalities: Genome safety perspectives on viral-, nuclease- and nucleotide-based gene therapies","volume":"896","author":"Lemmens","year":"2024","journal-title":"Mutat. Res. Genet. Toxicol. Environ. Mutagen."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jcyt.2022.09.004","article-title":"Digital polymerase chain reaction strategies for accurate and precise detection of vector copy number in CAR T cell products","volume":"25","author":"Murphy","year":"2023","journal-title":"Cytotherapy"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/s41467-023-37508-7","article-title":"Cytosine base editors induce off-target mutations and adverse phenotypic effects in transgenic mice","volume":"14","author":"Yan","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00294-021-01211-1","article-title":"Off-target effects of base editors: What we know and how we can reduce it","volume":"68","author":"Slesarenko","year":"2022","journal-title":"Curr. Genet."},{"key":"ref_86","first-page":"2698","article-title":"Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering","volume":"141","author":"Odak","year":"2023","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e2313226","DOI":"10.1002\/adma.202313226","article-title":"Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy","volume":"36","author":"Metzloff","year":"2024","journal-title":"Adv. Mater."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tibtech.2023.08.005","article-title":"Chimeric antigen receptor therapy meets mRNA technology","volume":"42","author":"Wu","year":"2024","journal-title":"Trends Biotech."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.37349\/etat.2023.00186","article-title":"A decade of CD4+ chimeric antigen receptor T-cell evolution in two chronic lymphocytic leukemia patients: Were chronic lymphocytic leukemia cells present?","volume":"4","author":"Bouzianas","year":"2023","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2321678","DOI":"10.1080\/21645515.2024.2321678","article-title":"First pediatric B-acute lymphoblastic leukemia patient treated with anti-CD19 chimeric antigen receptor T-cell therapy: Long-term remission or early cure?","volume":"20","author":"Bouzianas","year":"2024","journal-title":"Hum. Vaccines Immunother."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9518\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:46:42Z","timestamp":1760111202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":90,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ijms25179518"],"URL":"https:\/\/doi.org\/10.3390\/ijms25179518","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}